Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate the Safety and Effectiveness of Different Doses of Chrysalin in Adults Who Have a Broken Wrist

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00131482
Recruitment Status : Terminated (Treatment with Chrysalin did not demonstrate benefit compared to placebo.)
First Posted : August 18, 2005
Last Update Posted : August 24, 2010
Sponsor:
Information provided by:
Capstone Therapeutics

Tracking Information
First Submitted Date  ICMJE August 16, 2005
First Posted Date  ICMJE August 18, 2005
Last Update Posted Date August 24, 2010
Study Start Date  ICMJE November 2004
Actual Primary Completion Date March 2007   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: August 23, 2010)
Time to removal of all rigid immobilization for fracture [ Time Frame: Assessed Weeks 1-8, and Weeks 10, 12 and 26 after treatment ]
Original Primary Outcome Measures  ICMJE
 (submitted: August 16, 2005)
Time to removal of all rigid immobilization for fracture
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: August 23, 2010)
  • Time to clinical healing of the fracture [ Time Frame: Assessed Weeks 1-8, and Weeks 10, 12 and 26 after treatment ]
  • Time to radiographic healing of the fracture [ Time Frame: Assessed Weeks 1-8, and Weeks 10, 12 and 26 after treatment ]
  • Assessment of range of motion relative to unbroken wrist [ Time Frame: Assessed Weeks 1-8, and Weeks 10, 12 and 26 after treatment ]
  • Assessment of grip strength relative to unbroken wrist [ Time Frame: Assessed Weeks 1-8, and Weeks 10, 12 and 26 after treatment ]
  • Results of patient questionnaires [ Time Frame: Questionnaires given Weeks 4, 6, 8, 10,12 and 26 after treatment ]
  • Incidence of treatment-emergent adverse events [ Time Frame: Weeks 1-8, and Weeks 10, 12, 26 and 52 after treatment ]
  • Chemistry and hematology laboratory evaluations [ Time Frame: Within 24 hours, and at Weeks 2, 4, 8, and 26 after treatment ]
Original Secondary Outcome Measures  ICMJE
 (submitted: August 16, 2005)
  • Time to clinical healing
  • Time to radiographic healing
  • Assessment of range of motion relative to unbroken wrist
  • Assessment of grip strength relative to unbroken wrist
  • Results of patient questionnaires
  • Incidence of treatment-emergent adverse events up to 52 wks
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Study to Evaluate the Safety and Effectiveness of Different Doses of Chrysalin in Adults Who Have a Broken Wrist
Official Title  ICMJE A Double-blind, Randomized, Placebo-controlled Phase 2b Study to Establish the Effective Dose Range and to Evaluate the Safety of Chrysalin in Adult Subjects With a Fractured Distal Radius
Brief Summary The purpose of this study is to evaluate the safety of Chrysalin, also known as TP508, and to determine the effectiveness of four doses of Chrysalin for treating broken wrists in adults.
Detailed Description There is a medical need for a product that is safe and can accelerate the rate of bone healing, leading to a reduction in immobilization time. Chrysalin, also known as TP508, is a synthetic peptide (protein) that is an exact copy of part of the human protein thrombin, which is a protein that occurs naturally in the body. Chrysalin can be used to mimic part of the thrombin response after injury without stimulating any of the events associated with blood clotting, and can therefore accelerate the normal process of healing.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Radius Fracture
Intervention  ICMJE
  • Drug: Chrysalin
    Patients were treated with a single percutaneous injection of Chrysalin 3 micrograms at the fracture site at the time of surgery.
  • Drug: Chrysalin
    Patients were treated with a single percutaneous administration of Chrysalin 1 microgram at the fracture site at the time of surgery.
  • Drug: Chrysalin
    Patients were treated with a single percutaneous administration of Chrysalin 10 micrograms at the fracture site at the time of surgery.
  • Drug: Chrysalin
    Patients were treated with a single percutaneous administration of Chrysalin 30 micrograms at the fracture site at the time of surgery.
  • Drug: Placebo
    Patients were treated with a single percutaneous administration of placebo at the fracture site at the time of surgery.
Study Arms  ICMJE
  • Experimental: 10 micrograms
    Intervention: Drug: Chrysalin
  • Experimental: 30 micrograms
    Intervention: Drug: Chrysalin
  • Placebo Comparator: Placebo
    Intervention: Drug: Placebo
  • Experimental: 3 micrograms
    Intervention: Drug: Chrysalin
  • Experimental: 1 microgram
    Intervention: Drug: Chrysalin
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: August 23, 2010)
274
Original Enrollment  ICMJE
 (submitted: August 16, 2005)
500
Actual Study Completion Date  ICMJE March 2007
Actual Primary Completion Date March 2007   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • An unstable and/or displaced fracture of the distal radius
  • Fracture classified as primary intra-articular or extra-articular
  • Male, or non-pregnant, non-lactating female at least 18 years old. If female of childbearing potential, must have confirmed negative pregnancy test prior to administration of study product. Must agree to use a medically approved method of birth control for 6 months.
  • Need ability to understand study requirements, provide written informed consent, and comply with study protocol
  • Need ability to understand and provide written authorization for use and disclosure of health information per Health Insurance Portability and Accountability Act (HIPAA)

Exclusion Criteria:

  • History of distal radius fracture of the affected limb 2 years prior to study enrollment
  • History of uncontrolled Type I or Type II diabetes mellitus
  • History or clinical evidence of any active medical disease or condition which would make the subject, in the opinion of the investigator, unsuitable for the study, or could potentially confound the results of the study
  • Concurrent use of other investigational (non-Food and Drug Administration [FDA]-approved) agent or device
  • Participation in any other clinical study within 90 days prior to treatment with the study drug
  • Female subjects who are pregnant or nursing
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00131482
Other Study ID Numbers  ICMJE OL-ADRFX-03
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Denise Lamon, Director, Regulatory Affairs, Capstone Therapeutics
Study Sponsor  ICMJE Capstone Therapeutics
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Chair: James Ryaby, Ph.D. Capstone Therapeutics
PRS Account Capstone Therapeutics
Verification Date August 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP